ADVB Advanced Biomed: Earnings per share for the trailing year
Advanced Biomed Inc (ADVB) is developing microfluidic systems for rapid blood cancer analysis, generating revenue from consumables. On GURU.Markets, this annual EPS TTM shift reflects a trend where the metric remains around 14.60. However, the pre-commercial development stage limits profit scaling. Investors should consider the risks of clinical failures and the company's dependence on external financing.
%20Advanced%20Biomed&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_ADVB_-_Advanced-Biomed-Inc_-_Net-earnings-per-share-EPS-TTM "ADVB (Advanced Biomed Corp) Net earnings per one share for the last twelve months history from 11/23/2025 to 11/12/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Advanced Biomed Corp (ADVB)
- current quotes and average value forecast:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Debt to Equity Ratio Advanced Biomed Inc|ADVB - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Advanced Biomed Inc|ADVB - Company Aggregate Debts|Debts to Book Capitalization Advanced Biomed Inc.|ADVB - Company Long-Term Debt|Company Short-Term Indebtedness Advanced Biomed|Quick Liquidity Indicator advanbiomed.com
- net income and valuation ratios data:
ADVB - Net Profit|Expected Net Profit Advanced Biomed Inc|ADVB - P/E Multiple|Price to Future Earnings Ratio Advanced Biomed Inc|ADVB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Advanced Biomed Inc.|ADVB - Operating profit EBITDA|Earnings per share for the last twelve months Advanced Biomed|ADVB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months advanbiomed.com|ADVB - Earnings per share growth in current year|Expected net earnings per share growth next year Advanced Biomed Inc
Fundamental company valuation:ADVB - Advanced Biomed
For Advanced Biomed Inc (ADVB), whose model depends on risky clinical trials, the 12-month YoY EPS growth rate reflects the company's ability to convert external capital into actual profit. This indicator compares net earnings per share over the last four quarters with the same period last year, allowing investors to promptly identify asset stagnation amid the high uncertainty of medical developments.
Competitor analysis
ONC - Net earnings per share (EPS TTM)|Halozyme (HALO) - Earnings per share for the last twelve months|Revolution Medicines Inc - Earnings per share for the trailing year|AAPG (Ascentage) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology Therapeutics CGON|Net earnings per share (EPS TTM) URGN|Net earnings per share (EPS TTM) bicara.com (BCAX)|Net earnings per share (EPS TTM) PSNL (Personalis)|ERAS: Earnings per share for the last 12 months|DCTH: Net earnings per share for the last 12 months|YMAB: Earnings per share for the last twelve months|AURA: Net earnings per share (EPS TTM)|Candel Therapeutics, Inc. (CADL) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Accuray|Earnings per share for the last 12 months SLS (SELLAS Life Sciences Group Inc.)|Net earnings per share (EPS TTM) ACTU|Net earnings per share for the last 12 months Citius Oncology Inc CTOR|Net earnings per share (EPS TTM) HURA (TuHURA Biosciences)|protaratx.com (TARA) - Net earnings per one share for the last twelve months|Fate Therapeutics - Net earnings per share (EPS TTM)|WHWK (Aadi Bioscience Inc) - Earnings per share for the last 12 months|TCRX (tscan.com) - Net earnings per share for the last 12 months|Champions Oncology, Inc. - Earnings per share for the trailing year|XBIT (XBiotech Inc) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months CVM|Net earnings per share (EPS TTM) OSTX|Net earnings per share for the last four quarters Radiopharm Theranostics Ltd|Earnings per share for the last twelve months Artiva Biotherapeutics ARTV|Adlai Nortye Ltd (ANL) - Net earnings per one share for the last twelve months|VERU - Earnings per share for the last twelve months|tempesttx.com (TPST) - Net earnings per share for the last 12 months|XLO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Renovaro (RENB)|MURA (Mural Oncology PLC) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months KAPA (Kairos Pharma Inc)|Net earnings per share for the last 12 months OKUR (OnKure Therapeutics Inc)|GDTC (w2.cytomed.sg) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) CRIS (Curis)|Net earnings per share for the last four quarters Apollomics Inc. (APLM)|THAR - Earnings per share for the last twelve months|GNPX (Genprex Inc) - Earnings per share for the last 12 months|CLDI: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Sunshine Biopharma Inc.|XBIO (Xenetic Biosciences Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Salarius Pharmaceuticals Inc|Net earnings per share (EPS TTM) PPBT|aoncology.com - Earnings per share for the last 12 months|BeiGene, Ltd. - Net earnings per share for the last 12 months|checkpointtx.com - Earnings per share for the last twelve months|Elevation Oncology, Inc. - Net earnings per share (EPS TTM)|ICAD: Earnings per share for the last twelve months|IKNA: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Notable Labs Corp|VIRX (Viracta Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) morphosys.com|Earnings per share for the last twelve months NAYA Biosciences Inc. (NAYA)|Ascentage Pharma Group International - Earnings per share for the last 12 months
